We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cognitive Function in Elderly Marathon Runners (APSOEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01045031
Recruitment Status : Active, not recruiting
First Posted : January 8, 2010
Results First Posted : July 11, 2016
Last Update Posted : July 11, 2016
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:

There is substantial research on the effects of physical exercise on cognitive functions. However, less attention has been paid on the requirements of training intensity and length to enhance cognitive abilities in the elderly. To the investigators knowledge no studies have evaluated the effects of extensive endurance exercise training on cognitive functions by studying elderly marathon runners and bicyclists. On the basis of the scientific literature published so far it is not known whether the beneficial impact of endurance exercise training depends on the intensity of training.

The investigators therefore designed a cohort study with adequate power in order to evaluate the effects of intensive endurance exercise training on cognition. This trial, an Austrian prospective cohort study in cognitive function of elderly marathon-runners (APSOEM) is being conducted and will compare neuropsychological performance outcomes of elderly marathon runners or bicyclists with controls matched concerning age, education years, occupation, and verbal intelligence.


Condition or disease
Cognitive Decline

  Show Detailed Description

Study Design

Study Type : Observational
Actual Enrollment : 114 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Austrian Prospective Cohort Study in Cognitive Function of Elderly Marathon-runners
Study Start Date : December 2008
Primary Completion Date : February 2014
Estimated Study Completion Date : December 2018
Groups and Cohorts

Group/Cohort
Controls
Controls were subsequently contacted via personal contact and three additional advertisements (two in an Austrian newspaper ("Krone") and one in an Austrian bicyclist journal ("Bicyclist Sports"). The controls were matched according to age, sex and years of education
marathon athletes
Runners participating in the 2008 Wachau half marathon (21,2 km) and the Vienna City marathon (42,5 km) as well as bicyclists participating at the Corinthian marathon (180km). Inclusion criteria:1) participation in at least one of these 3 marathons in the preceding two years,2)still in continuous training during the recruitment phase (at least 2 hours/week), 3) aged over 60. Exclusion criteria:(a) present or past exposure to neurotoxic substances (b) if they did not speak German as their native language (c) diseases that markedly affect CNS functions (d) manifest cardiovascular disease, (e) chronic alcoholism (daily alcohol intake > 60 g or diagnosed history of alcoholism) and (f) unwillingness to give informed consent.


Outcome Measures

Primary Outcome Measures :
  1. the Proportion of Subjects, Who Will Develop Mild Cognitive Impairment [ Time Frame: 10 years ]
    Hypothesis will be tested at the second follow-up examinations.

  2. Brain-derived Neurotrophic Factor (BDNF) [ Time Frame: Baseline and 5 years ]

Secondary Outcome Measures :
  1. Self Rating by Questionnaires [ Time Frame: Baseline and 5 years ]
    The following self rating scales were used: WHO-5 Quality of Life Assessment (Braeher, E., Muehlan, H., Albani, C., & Schmidt, S. (2007). Testing and standardization of the German version of the EUROHIS-QOL and WHO-5 quality-of life-indices. Diagnostica, 53(2), 83-96.). Range: 0 - 25, higher scores indicate better quality of life.

  2. Insulin-like Growth Factor (IGF-1) [ Time Frame: Baseline and 5 years ]

Biospecimen Retention:   Samples With DNA
Apolipoprotein E4 genotype, Insulin-like growth factor-1, Brain-derived neurotrophic factor, rs6265-Genotype

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Marathon runners, bicyclists and controls from the greater Vienna area
Criteria

Inclusion Criteria:

  • Current Marathon runners or marathon bicyclists and controls from the greater Vienna area

Exclusion Criteria:

  • Current of past neurotoxic exposure
  • Not German as native language
  • Diseases, that might affect central nervous system (stroke, meningitis, meningeoma, hydrocephalus,..)
  • Manifest cardiovascular disease
  • Alcoholism
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Robert Winker, Ass. Prof., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01045031     History of Changes
Other Study ID Numbers: Grant Project number 12979
First Posted: January 8, 2010    Key Record Dates
Results First Posted: July 11, 2016
Last Update Posted: July 11, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Robert Winker, Medical University of Vienna:
cognitive function, aging, brain-derived neurotrophic factor

Additional relevant MeSH terms:
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders